Research Article

Concomitant Treatment with Etanercept and Tacrolimus Synergistically Attenuates Arthritis Progression via Inhibition of Matrix Metalloproteinase-3 Production and Osteoclastogenesis in Human TNF-α Transgenic Mice

Figure 4

Etanercept and tacrolimus decrease the population of CD11bhigh peripheral osteoclast precursors in hTNF-Tg mice. Etanercept (ETN; 4 mg/kg) was administered subcutaneously twice a week for 4 weeks, and tacrolimus (TAC; 3 mg/kg) was administered orally once daily for 4 weeks. (a) Percentages of ZombieNIR-negative CD11bhigh cells in splenic cells derived from individual mice are shown. Each horizontal bar shows the mean of six animals per group. , , and compared with the vehicle group (Dunnet’s multiple comparison test). compared with the tacrolimus-treated group (Student’s -test). (b) Representative plots of each drug treatment group are shown. Data are representative of two independent experiments.
(a)
(b)